Excision BioTherapeutics is a biopharmaceutical company based in San Francisco focused on developing gene therapies against HIV infection.

The company has a single, CRISPR–Cas9 based therapy, EBT-101, under investigation. Initial investigation into the therapy was conducted by the lab of Kamel Khalili, a professor at Temple University.[1][2][3][4] In July, 2023 the US Food and Drug Administration granted EBT-101 fast-track status.[5] In October 2023 an early-stage study on 3 people reported that the treatment appeared to be safe with no major side effects but no data on its effectiveness was disclosed.[6]

See also

References

  1. ^ Sheldon, Cormac (30 October 2023). "Armed with gene technologies and CAR-Ts, scientists are attempting to eliminate viruses that escape immune detection and lurk in tissues for years". Nature Medicine. 41 (11): 1491–1493. doi:10.1038/s41587-023-02022-0. S2CID 264673741. Retrieved 16 November 2023.
  2. ^ "The first human study has launched to treat HIV patients with CRISPR. The CEO of the gene-editing startup says it could be a one-time cure". Business Insider. 27 January 2023. Retrieved 16 November 2023.
  3. ^ Brzyski, Laura (5 March 2023). "Excision BioTherapeutics Has Secured $60M to Proceed with HIV Clinical Trial". Philadelphia. Retrieved 16 November 2023.
  4. ^ Krieger, Lisa (28 October 2023). "CRISPR gene editing could kill HIV. But is it a cure?". The Mercury News. Retrieved 16 November 2023.
  5. ^ Leuty, Ron (21 July 2023). "S.F. biotech inches closer to potential HIV cure with key move by FDA". San Francisco Business Times. Retrieved 17 November 2023.
  6. ^ "Three people were gene-edited in an effort to cure their HIV. The result is unknown". MIT Technology Review. Retrieved 2024-03-20.